LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

LENZ Therapeutics, Inc.NASDAQ: LENZ

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at 37.6%

Gross margin was 37.6% in Q1 FY2026. On a trailing-twelve-month basis it was 91.2%. Over 3 fiscal years it narrowed by 3.7 pp.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
37.6%-29.4 pp QoQ
Last fiscal yearDec 2025
96.3%— YoY
LTMMar 2026
91.2%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years-3.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
96.3%
Year-over-year change
—

Gross Margin vs competitors

How LENZ compares with its peers on the latest reported figures

  • LENZ's LTM Mar 2026 gross margin of 91.2% is the 3rd highest of the 7 companies compared; the peer median is 81.8%.
  • Over three fiscal years its change of -3.7 pp compares with a peer median of -2.6 pp.
LENZ Competitors Peer median
Gross Margin for LENZ and competitors
Company Period LTM level YoY 3-year change
NBTXNanobiotix S.A.FY2025100.0% +0.0 pp+0.0 pp
ABUSArbutus Biopharma CorporationLTM Mar 2026100.0% +277.5 pp-2.6 pp
LENZLENZ Therapeutics, Inc.LTM Mar 202691.2% —-3.7 pp
GERNGeron CorporationLTM Mar 202686.6% -11.3 pp-2.6 pp
SPRYARS Pharmaceuticals, Inc.LTM Mar 202677.1% -7.5 pp+1276.7 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 202634.6% +5.5 pp-62.9 pp
PRMEPrime Medicine, Inc.LTM Mar 2026-1082.7% -1182.7 pp—
TYRATyra Biosciences, Inc.FY2025— ——
GHRSGH Research PLCFY2025— ——
SVRASavara Inc.FY2025— ——
RZLTRezolute, Inc.FY2025— ——
Peer median (excluding LENZ) 81.8%-3.8 pp-2.6 pp

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue015M0019.09M
Cost of Revenue734K0058K705K
Gross Profit(734K)15M0(58K)18.38M
Gross Margin—100.0%——96.3%
Research & Development37.93M21.13M59.5M29.8M18.67M
Selling, General & Admin21.78M4.36M12.93M28.75M90.85M
Operating Expenses59.71M25.48M72.43M58.55M109.52M
Depreciation & Amortization734K8K15K58K287K
EBITDA(70.03M)(10.46M)(70.13M)(49.71M)(81.34M)
EBITDA Margin—-69.7%——-426.1%
Operating Income(60.44M)(10.48M)(72.43M)(58.61M)(91.14M)
Operating Margin—-69.9%——-477.5%
Interest Income002.19M8.55M9.76M
Interest Expense00000
Other Income / Expenses(10.32M)19K2.28M8.84M9.51M
Income Before Tax(70.76M)(10.46M)(70.15M)(49.77M)(81.63M)
Pre-Tax Margin—-69.8%——-427.6%
Income Tax Expense0347K(179K)1K502K
Net Income(70.76M)(10.81M)(69.97M)(49.77M)(82.13M)
Net Margin—-72.1%——-430.3%
EPS (Basic)(8.54)(12.89)(15.30)(2.34)(2.85)
EPS (Diluted)(8.54)(12.89)(15.30)(2.34)(2.85)
Weighted Avg Shares8.29M7.84M8.15M21.28M28.81M
Weighted Avg Shares (Diluted)8.29M7.84M8.15M21.28M28.81M

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.